drugset / Trial / NCT06310304

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

NCT06310304

Phase 1 Completed 24 enrolled Incyte Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants.

Timeline

Start
2024-03-26
Primary completion
2024-04-16
Completion
2024-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule Oral

Indications

No indication recorded.